세계의 플루옥세틴 시장 보고서(2025년)

Fluoxetine, classified as a selective serotonin reuptake inhibitor (SSRI), is widely utilized as an antidepressant and for various psychiatric conditions. Its mechanism involves boosting serotonin levels, a neurotransmitter crucial for regulating mood, emotions, and behavior in the brain. Prescribed commonly for depression, fluoxetine aids in enhancing sleep, appetite, and energy levels among individuals with major depressive disorder.

Fluoxetine is available in diverse forms such as tablets, solutions, capsules, and syrups. Tablets, a solid oral dosage form, dissolve in the stomach upon ingestion and are administered to adults, children, and the elderly. This medication is frequently prescribed for conditions including obsessive-compulsive disorder, panic disorder, depression, and bulimia nervosa. It is utilized across various settings such as clinics and hospitals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The fluoxetine market research report is one of a series of new reports from The Business Research Company that provides fluoxetine market statistics, including fluoxetine industry global market size, regional shares, competitors with a fluoxetine market share, detailed fluoxetine market segments, market trends and opportunities, and any further data you may need to thrive in the fluoxetine industry. This fluoxetine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fluoxetine market size has grown steadily in recent years. It will grow from $0.99 billion in 2024 to $1.03 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increased rates of depression and anxiety disorders, enhanced awareness and de-stigmatization of mental health issues, improved healthcare infrastructure, an aging global population, and the availability of cost-effective generic fluoxetine.

The fluoxetine market size is expected to see steady growth in the next few years. It will grow to $1.23 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to government initiatives and funding for mental health programs, public health campaigns promoting mental well-being, increasing discussion and awareness of mental health issues on social media platforms, the rise of online pharmacies, cultural shifts towards accepting and addressing mental health issues. Major trends in the forecast period include advances in diagnostic methods leading to early detection, the rise of telemedicine facilitates, advances in drug delivery systems, AI and machine learning are increasingly used in drug discovery and development, and developments in pharmacogenomics.

The forecast of 4.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. mental health treatment by inflating prices of generic fluoxetine capsules and oral solutions manufactured in India and Israel, resulting in reduced antidepressant affordability and higher psychiatric care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of mental health disorders is anticipated to drive the expansion of the fluoxetine market in the future. Mental health disorders encompass a wide spectrum of conditions affecting cognitive, emotional, and behavioral functions, resulting in distress or impairment in daily life. Factors contributing to the rise in these disorders include societal pressures, economic challenges, lifestyle shifts, and improved awareness and diagnosis. Fluoxetine is utilized in the treatment of mental health disorders because it alleviates symptoms by enhancing serotonin levels in the brain, crucial for regulating mood and emotions. For example, a survey conducted in November 2022 by the National Health Service, a UK government-funded healthcare system, revealed that approximately 18.0% of children aged 7 to 16 and 22.0% of young individuals aged 17 to 24 potentially had a mental disorder in 2022. Specifically, the prevalence of likely mental disorders among young people aged 17 to 19 increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the rising prevalence of mental health disorders is a significant factor propelling the growth of the fluoxetine market.

The fluoxetine market is anticipated to experience growth due to the rise in healthcare expenditure. This increase is driven by factors such as the escalating costs of advanced medical technologies, aging populations, and the prevalence of chronic diseases. As healthcare spending rises, it improves the accessibility and affordability of medications such as fluoxetine, which benefits patients requiring treatment for depression and anxiety disorders by enhancing access and adherence. Consequently, this can lead to better mental health outcomes overall and reduce long-term healthcare expenses. For example, in January 2024, healthcare expenditure in the US surged by 4.1% in 2022 to $4.5 trillion, marking a faster growth rate compared to the 3.2% increase seen in 2021, as reported by the National Institutes of Health, a US government agency.

Key players in the fluoxetine market are concentrating on innovating products such as fluoxetine tablets for treating various mental health disorders such as major depressive disorder. Fluoxetine tablets contain fluoxetine hydrochloride, an antidepressant classified as a selective serotonin reuptake inhibitor (SSRI). In April 2024, Strides Pharma Global Pte. Limited, a Singapore-based pharmaceutical company, received approval from the United States Food and Drug Administration (USFDA) for Fluoxetine Tabs 10 mg and 20 mg. This approval expands the company's fluoxetine product line by introducing tablets alongside the already-approved capsules. Fluoxetine, an SSRI, is used to treat conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder with or without agoraphobia. The introduction of fluoxetine tablets broadens the treatment options within the company's fluoxetine portfolio, providing patients and healthcare providers with more flexibility and choices in managing these mental health disorders.

Major companies operating in the fluoxetine market are Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hetero Ltd., Torrent Pharmaceuticals GmbH, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Apotex Inc., Amneal Pharmaceuticals Inc., Lupin Ltd., Glenmark Pharmaceuticals Inc., Alvogen, Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., PERRIGO Company plc, Wockhardt Ltd., Jubilant Life Sciences Ltd., Lannett Company Inc., Mayne Pharma International Pty Ltd., Par Pharmaceutical Companies Inc., Zydus Pharmaceuticals USA Inc., Ascend Laboratories LLC

North America was the largest region in the fluoxetine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluoxetine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fluoxetine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fluoxetine market consists of sales of fluoxetine hydrochloride tablets, fluoxetine powder, and fluoxetine injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fluoxetine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fluoxetine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fluoxetine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fluoxetine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Dosage Form: Tablet; Solution; Capsule; Syrup; Other Dosage Forms
• 2) By Route Of Administration: Oral; Other Routes Of Administration
• 3) By Demographic: Adult; Pediatric; Geriatric
• 4) By Application: Obsessive-Compulsive Disorder; Panic Disorder; Depression; Bulimia Nervosa; Other Applications
• 5) By End User: Clinic; Hospital; Other End Users
• Subsegments:
• 1) By Tablet: Regular Tablets; Extended-Release Tablets
• 2) By Solution: Oral Solution
• 3) By Capsule: Standard Capsules; Delayed-Release Capsules
• 4) By Syrup: Oral Syrup
• 5) By Other Dosage Forms: Injection Form; Topical Form
• Companies Mentioned: Eli Lilly and Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Hetero Ltd.; Torrent Pharmaceuticals GmbH; Aurobindo Pharma; Cadila Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Limited; Apotex Inc.; Amneal Pharmaceuticals Inc.; Lupin Ltd.; Glenmark Pharmaceuticals Inc.; Alvogen; Alembic Pharmaceuticals Limited; Accord Healthcare Ltd.; PERRIGO Company plc; Wockhardt Ltd.; Jubilant Life Sciences Ltd.; Lannett Company Inc.; Mayne Pharma International Pty Ltd.; Par Pharmaceutical Companies Inc.; Zydus Pharmaceuticals USA Inc.; Ascend Laboratories LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fluoxetine Market Characteristics

3. Fluoxetine Market Trends And Strategies

4. Fluoxetine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Fluoxetine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fluoxetine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fluoxetine Market Growth Rate Analysis
• 5.4. Global Fluoxetine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fluoxetine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fluoxetine Total Addressable Market (TAM)

6. Fluoxetine Market Segmentation

• 6.1. Global Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Solution
• Capsule
• Syrup
• Other Dosage Forms
• 6.2. Global Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Other Routes Of Administration
• 6.3. Global Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• Geriatric
• 6.4. Global Fluoxetine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obsessive-Compulsive Disorder
• Panic Disorder
• Depression
• Bulimia Nervosa
• Other Applications
• 6.5. Global Fluoxetine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End Users
• 6.6. Global Fluoxetine Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Tablets
• Extended-Release Tablets
• 6.7. Global Fluoxetine Market, Sub-Segmentation Of Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solution
• 6.8. Global Fluoxetine Market, Sub-Segmentation Of Capsule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Capsules
• Delayed-Release Capsules
• 6.9. Global Fluoxetine Market, Sub-Segmentation Of Syrup, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Syrup
• 6.10. Global Fluoxetine Market, Sub-Segmentation Of Other Dosage Forms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Form
• Topical Form

7. Fluoxetine Market Regional And Country Analysis

• 7.1. Global Fluoxetine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fluoxetine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fluoxetine Market

• 8.1. Asia-Pacific Fluoxetine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fluoxetine Market

• 9.1. China Fluoxetine Market Overview
• 9.2. China Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fluoxetine Market

• 10.1. India Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fluoxetine Market

• 11.1. Japan Fluoxetine Market Overview
• 11.2. Japan Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fluoxetine Market

• 12.1. Australia Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fluoxetine Market

• 13.1. Indonesia Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fluoxetine Market

• 14.1. South Korea Fluoxetine Market Overview
• 14.2. South Korea Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fluoxetine Market

• 15.1. Western Europe Fluoxetine Market Overview
• 15.2. Western Europe Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fluoxetine Market

• 16.1. UK Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fluoxetine Market

• 17.1. Germany Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fluoxetine Market

• 18.1. France Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fluoxetine Market

• 19.1. Italy Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fluoxetine Market

• 20.1. Spain Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fluoxetine Market

• 21.1. Eastern Europe Fluoxetine Market Overview
• 21.2. Eastern Europe Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fluoxetine Market

• 22.1. Russia Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fluoxetine Market

• 23.1. North America Fluoxetine Market Overview
• 23.2. North America Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fluoxetine Market

• 24.1. USA Fluoxetine Market Overview
• 24.2. USA Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fluoxetine Market

• 25.1. Canada Fluoxetine Market Overview
• 25.2. Canada Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fluoxetine Market

• 26.1. South America Fluoxetine Market Overview
• 26.2. South America Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fluoxetine Market

• 27.1. Brazil Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fluoxetine Market

• 28.1. Middle East Fluoxetine Market Overview
• 28.2. Middle East Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fluoxetine Market

• 29.1. Africa Fluoxetine Market Overview
• 29.2. Africa Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fluoxetine Market Competitive Landscape And Company Profiles

• 30.1. Fluoxetine Market Competitive Landscape
• 30.2. Fluoxetine Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hetero Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Fluoxetine Market Other Major And Innovative Companies

• 31.1. Torrent Pharmaceuticals GmbH
• 31.2. Aurobindo Pharma
• 31.3. Cadila Pharmaceuticals Ltd.
• 31.4. Dr. Reddy's Laboratories Limited
• 31.5. Apotex Inc.
• 31.6. Amneal Pharmaceuticals Inc.
• 31.7. Lupin Ltd.
• 31.8. Glenmark Pharmaceuticals Inc.
• 31.9. Alvogen
• 31.10. Alembic Pharmaceuticals Limited
• 31.11. Accord Healthcare Ltd.
• 31.12. PERRIGO Company plc
• 31.13. Wockhardt Ltd.
• 31.14. Jubilant Life Sciences Ltd.
• 31.15. Lannett Company Inc.

32. Global Fluoxetine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fluoxetine Market

34. Recent Developments In The Fluoxetine Market

35. Fluoxetine Market High Potential Countries, Segments and Strategies

• 35.1 Fluoxetine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fluoxetine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fluoxetine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer